Norwood Abbey

Norwood Abbey was an Australian medical technology company specializing in the development of needle-free drug delivery systems and immunology treatments. The company's primary platform was the Norwood Laser, a device designed to create microscopic pores in the skin to facilitate the rapid delivery of topical anesthetics and other drugs. Through its subsidiary, Norwood Immunology, the company explored therapies for immune system regeneration, specifically targeting the thymus gland using GnRH analogues. The company also developed technologies for needle-free injection and ophthalmic surgery through its various business units. While the company successfully brought products to market and was listed on the Australian Securities Exchange, it ultimately faced financial distress and ceased active operations.